Teva halts Phase 2 emrusolmin trial in multiple system atrophy after futility analysis
TEVA•Teva will discontinue its Phase 2 TOPAS-MSA trial after an interim analysis indicated a low probability of meeting its primary efficacy goal. No safety concerns emerged, and Teva has not made a final decision on the broader emrusolmin program partnered with MODAG.
1. Trial discontinuation
Teva will discontinue its Phase 2 TOPAS-MSA trial of emrusolmin in adults with multiple system atrophy. An interim assessment indicated a low probability of meeting the primary efficacy goal, but was not a final efficacy analysis; no safety concerns emerged.
2. Further review
Teva plans to review available open-label extension data and share comprehensive findings with the scientific community after further analysis. The broader emrusolmin program, partnered with MODAG, remains without a final decision.
